View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AI08 | Publication ID: Spring 2024 |
Title: Institutional Review Boards; Cooperative Research | |
Abstract:
This rule will replace current FDA requirements for cooperative research such that any institution located in the United States (U.S.) participating in multisite cooperative research will need to rely on approval by a single Institutional Review Board (IRB) for that portion of the research that is conducted in the U.S., with some exceptions. This rule will also establish an IRB recordkeeping requirement for research that takes place at an institution in which IRB oversight is conducted by an IRB that is not operated by the institution. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Section 3(f)(1) Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: Yes | Unfunded Mandates: Private Sector |
CFR Citation: 21 CFR 56 | |
Legal Authority: 21 U.S.C. 343 21 U.S.C. 346 21 U.S.C. 348 21 U.S.C. 350a and 350b 21 U.S.C. 353 21 U.S.C. 355 21 U.S.C. 360 21 U.S.C. 360c to 360e 21 U.S.C. 360j 21 U.S.C. 360hh to 360pp 21 U.S.C. 360rr to 360ss 21 U.S.C. 371 21 U.S.C. 379e 42 U.S.C. 262 |
Legal Deadline:
|
||||||||||||||||||
Overall Description of Deadline: Section 3023 of the 21st Century Cures Act |
||||||||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Darin Achilles Regulatory Counsel Department of Health and Human Services Food and Drug Administration Office of Clinical Policy, 10903 New Hampshire Avenue, WO 32, Room 5103, Silver Spring, MD 20993 Phone:301 796-4040 Email: darin.achilles@fda.hhs.gov |